ESMO 04/2017 Congress Report
Single articles:
• What is new in surgery? Redefining current options
• EGFR TKI therapy in specific populations and settings
• "We are making steady progress toward better lung cancer control"
• Taking anti-EGFR drug treatment further: later lines
• Immunotherapy: novel biomarkers on the horizon & news from pivotal trials
• Approaching squamous-cell carcinoma in a targeted manner
• Malignant mesothelioma: recent data on nintedanib and checkpoint inhibitors
• Chemotherapy: new approaches, new settings
• Survival is the result of lung cancer screening
Download the 2017 WCLC congress report: